Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33. Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its...
Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.085 | -11.1842105263 | 0.76 | 0.7993 | 0.638 | 830008 | 0.67441923 | CS |
4 | -0.1825 | -21.2827988338 | 0.8575 | 1.19 | 0.638 | 2022337 | 0.89805509 | CS |
12 | -0.2926 | -30.2397684994 | 0.9676 | 1.19 | 0.638 | 840687 | 0.90369146 | CS |
26 | -1.385 | -67.2330097087 | 2.06 | 2.23 | 0.638 | 571660 | 1.06456846 | CS |
52 | -1.275 | -65.3846153846 | 1.95 | 3.1399 | 0.638 | 399711 | 1.35990421 | CS |
156 | -14.885 | -95.6619537275 | 15.56 | 18.515 | 0.638 | 220317 | 3.21508915 | CS |
260 | -41.345 | -98.3936220847 | 42.02 | 63.62 | 0.638 | 214878 | 7.30528465 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約